Valneva SE (VLS.PA)
VLS.PA on Paris Stock Exchange
3.63EUR
18 Jan 2019
3.63EUR
18 Jan 2019
Change (% chg)
€-0.08 (-2.16%)
€-0.08 (-2.16%)
Prev Close
€3.71
€3.71
Open
€3.68
€3.68
Day's High
€3.72
€3.72
Day's Low
€3.56
€3.56
Volume
109,412
109,412
Avg. Vol
86,834
86,834
52-wk High
€4.19
€4.19
52-wk Low
€3.01
€3.01
About
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and... (more)
Overall
| Beta: | 1.88 |
| Market Cap(Mil.): | €226.54 |
| Shares Outstanding(Mil.): | 77.58 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| VLS.PA | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 69.71 | 33.71 |
| EPS (TTM): | -0.19 | -- | -- |
| ROI: | -8.43 | 8.99 | 14.48 |
| ROE: | -13.92 | 10.13 | 15.99 |
Emergent-Valneva Zika vaccine clears early trial
A vaccine to prevent infections caused by the deadly mosquito-borne Zika virus induced immune response and was found to be safe in an early stage trial, Emergent BioSolutions Inc and partner Valneva SE said on Monday.
Emergent-Valneva Zika vaccine clears early trial
Nov 19 A vaccine to prevent infections caused by the deadly mosquito-borne Zika virus induced immune response and was found to be safe in an early stage trial, Emergent BioSolutions Inc and partner Valneva SE said on Monday.
Estimates